UBS Maintains a 'Buy' on Merck (MRK); Odanacatib First Analysis Looking Good
Tweet Send to a Friend
UBS maintains a 'Buy' on Merck (NYSE: MRK) price target of $45.00.
Analyst, Marc Goodman, along with other Wall ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Marc Goodman, along with other Wall ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
